<DOC>
	<DOCNO>NCT02315287</DOCNO>
	<brief_summary>Triple combination metformin , DPP4 inhibitor Thiazolidinedione would good option treatment drug-naïve Korean type 2 diabetic patient . Newly develop thiazolidinedione , Lobeglitazone would inferior Pioglitazone .</brief_summary>
	<brief_title>Triple Combination Metformin , Sitagliptin Thiazolidinedione Drug-naïve Type 2 Diabetic Patients</brief_title>
	<detailed_description>Thiazolidionedione , PPARgamma agonist , strong insulin sensitizer . It show durable glucose lower effect beta cell preservation . It important treatment option patient type 2 diabetes . It well establish inhibition dipeptidyl peptidase-4 ( DPP-4 ) reduce blood glucose level fast postprandial state , preserve pancreatic β-cell function patient type 2 diabetes . The mechanism action DPP-4 inhibitor increase level active incretin , glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) , stimulate insulin secretion well insulin biosynthesis inhibit glucagon release pancreatic islet . DPP4 inhibitor also well safety tolerability profile ( e.g. , weight neutrality less hypoglycemia ) compare hypoglycemic agent . When consider combination therapy DPP-4 inhibitor , metformin commonly use agent show effective well tolerated previous study . Besides glucose lower effect reduce hepatic glucose output improve insulin resistance , metformin without inhibit DPP-4 activity , also increase active GLP-1 concentration 1.5- 2-fold follow oral glucose load obese , nondiabetic subject . Accordingly , effect metformin may provide unique benefit combine DPP-4 inhibitor substantial enhancement incretin axis , provide effective potentially additive glycemic improvement . Because favorable pharmacological property , combination DPP-4 inhibitor , metformin , thiazolidinedione increasingly use achieve rapid glycemic goal low risk hypoglycemia weight gain , delay need subsequent regimen change . DPP-4 inhibitor block DPP-4 enzyme preserve endogenous incretins whereas metformin increase active form GLP-1 , may enhance secretory function pancreas . However , response DPP-4 inhibitor metformin combination therapy may different individual accord pancreatic function insulin resistance status . In fact , previous study DPP-4 inhibitor show different potency glycemic control depend various patient characteristic include severity diabetes use antidiabetic drug.Consequently , would clinically important investigate effect triple combination therapy .</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>HbA1c &gt; =10.0 % No treatment insulin oral agent 6 month 20 ≤ Age &lt; 80 year Contraindication sitagliptin metformin thiazolidinedione Pregnant breast feed woman Type 1 diabetes , gestational diabetes , secondary form diabetes Not appropriate oral antidiabetic agent Medication affect glycemic control Disease affect efficacy safety drug Any major illness ( Liver disease , Renal failure , Heart disease , Cancer , etc )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Triple combination</keyword>
	<keyword>Metformin</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Lobeglitazone</keyword>
</DOC>